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ReFeRenCeS
BACkgRounD
The increasing incidence of hepatocellular 
carcinoma in Western countries has led to an 
expanding interest in this field. A vast need of 
experimental models that mimic the natural 
pathogenesis of hepatocellular carcinoma in a 
short time period is present. The goal of our study 
was (1) to develop an efficient mouse model for 
hepatocellular carcinoma research, (2) to assess 
time-dependent changes angiogenic pathways 
and (3) to investigate tumour growth and neo-
vascularisation using state-of-the-art imaging 
techniques.
MeTHoDS 
5-week-old male mice received weekly 
intraperitoneal injections with n-nitrosodiethylamine 
(Den) (35 mg/kg bodyweight) and samples were 
taken at several time points. Histology, eLISA and 
immunohistochemical stainings were used to identify 
the HCC-lesions and to quantify angiogenic factors 
VegF and PlgF; and their receptors. HCC livers 
(25W) were perfused with Batson’s n°17 solution 
to produce vascular casts (arterial and venous). 
A state-of-the-art multimodal microPeT/CT was 
used for in vivo detection for 3D-reconstruction of 
the vascular casts.
ReSuLTS
After 16W of DEN-injections a mild fibrosis (F1-
F2) and dysplastic lesions appear, resulting in 
a pre-malignant environment. An increase of 
angiogenic factors VegF and PlgF takes place, 
but not explicit enough to induce an increase in 
endothelial cells, which were upregulated after 
20W. After 25W of Den-injections, the dysplastic 
lesions have progressed to vascularised exophytic 
tumours which are macroscopically visible and 
give rise to a further increase in angiogenic 
factors, activating the angiogenic pathway and 
leading to the formation of new blood vessels.  
The vascular casts of HCC-livers clearly 
revealed the chaotic pattern and hierarchically 
disorganisation of tumour induced blood vessels. 
Arteries formed a circumferential mantle around 
the hepatic tumours, while the central tumour 
regions showed a lower arterial density. electron 
microscopy revealed several angiogenic spots, 
with mostly sprouting angiogenesis, furthermore 
intussusceptive  angiogenesis was also seen.
 gehoord
ConCLuSIon
While most Den-induced models take at least one 
year to develop tumours, weekly injections with 
Den give rise to tumour occurrence after 25W. 
The well vascularised orthotopic tumours are a 
representative model for HCC and can serve as 
an excellent platform for the development of new 
therapeutic targets. The histological and serological 
increase of angiogenic factors (PlgF & VegF), 
clearly give rise to new blood vessel formation, 
confirmed by endothelial cell quantification and 
CT-reconstructions of vascular casts. 
High levels of VegF can predict vascular invasion 
of HCC and correlated with poor prognosis [1-2]. 
elevated VegF is also a marker for poor response 
to locoregional treatment and is correlated with 
early recurrence [3-4]. PlgF levels are known to be 
elevated in a variety of cancers and is associated 
with poor prognosis in HCC [5-6]. The up-regulation 
of PlgF in this Den-model supports the theory that 
PlgF plays an essential role in the angiogenesis of 
HCC.
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Angiogenesis
up till now VegF, was one of the key targets in 
tumour induced angiogenesis, but recently PLgF 
gained interest because its association with 
pathological conditions. Both VegF and PLgF can 
bind to VegFR1, though only the latter can induce 
signal transduction leading to neo-vascularisation 
and arteriogenesis. Soluble VegF receptors are 
known to capture VegF without inducing signal 
transduction and therefore serve as decoy receptors.
Soluble vascular endothelial growth factor receptor-1 
(sVegFR1), a naturally occurring soluble form 
of the VegF receptor1, is an important negative 
counterpart of the VegF signalling pathway. 
Therefore, we measured the serum levels of 
sVegFR1. There was a slight increase of sVegFR1 
at 30W DEN treatment, but no significant difference 
was seen between controls and 25W Den
protein levels of VegF in liver tissue. Asterisks (*) 
represent the significant P-values of the control 
group compared to Den-groups (* = p<0,05; ** = 
p<0,01 and *** = p < 0,001). These data support 
the theory that PLgF plays an important role in 
the pathogenesis of HCC.
protein levels of PlgF in liver tissue, the vast up-
regulation of PlgF in liver tissue after 30W Den 
veils the 2.4x increase at 25W 
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ReFeRenCeS
BACkGRoUnD
The increasing incidence of hepatocellular carcinoma 
in Western countries has led to an expanding interest 
in this field. A vast need of experimental models that 
mimic the natural pathogenesis of hepatocellular 
carcinoma in a short time period is present. The goal of 
our study was (1) to develop an efficient mouse model 
for hepatocellular carcinoma research, (2) to assess 
time-dependent changes angiogenic pathways and (3) 
to investigate tumour growth and neo-vascularisation 
using state-of-the-art imaging techniques.
MeTHoDS 
5-week-old male mice received weekly intraperitoneal 
injections with n-nitrosodiethylamine (Den) (35 mg/kg 
bodyweight) and samples were taken at several time 
points. Histology, eLISA and immunohistochemical 
stainings were used to identify the HCC-lesions and to 
quantify angiogenic factors VeGF and PlGF; and their 
receptors. HCC livers (25W) were perfused with Batson’s 
n°17 solution to produce vascular casts (arterial and 
venous).  A state-of-the-art multimodal microPeT/CT 
was used for in vivo detection for 3D-reconstruction of 
the vascular casts.
ReSULTS
After 16W of Den-injections a mild fibrosis (F1-F2) and 
dysplastic lesions appear, resulting in a pre-malignant 
environment. An increase of angiogenic factors VeGF 
and PlGF takes place, but not explicit enough to induce 
an increase in endothelial cells, which were upregulated 
after 20W. After 25W of Den-injections, the dysplastic 
lesions have progressed to vascularised exophytic 
tumours which are macroscopically visible and give rise 
to a further increase in angiogenic factors, activating 
the angiogenic pathway and leading to the formation of 
new blood vessels.  
The vascular casts of HCC-livers clearly revealed the 
chaotic pattern and hierarchically disorganisation 
of tumour induced blood vessels. Arteries formed a 
circumferential mantle around the hepatic tumours, 
while the central tumour regions showed a lower 
arterial density. electron microscopy revealed several 
angiogenic spots, with mostly sprouting angiogenesis, 
furthermore intussusceptive  angiogenesis was also 
seen.
 gehoord
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Angiogenesis
Up till now VeGF, was one of the key targets in tumour induced 
angiogenesis, but recently PLGF gained interest because its association 
with pathological conditions. Both VeGF and PLGF can bind to VeGFR1, 
though only the latter can induce signal transduction leading to neo-
vascularisation and arteriogenesis. Soluble VeGF receptors are known 
to capture VeGF without inducing signal transduction and therefore 
serve as decoy receptors.
ConCLUSIon
While most Den-induced models take at least one year 
to develop tumours, weekly injections with Den give rise 
to tumour occurrence after 25W. The well vascularised 
orthotopic tumours are a representative model for 
HCC and can serve as an excellent platform for the 
development of new therapeutic targets. The histological 
and serological increase of angiogenic factors (PlGF & 
VeGF), clearly give rise to new blood vessel formation, 
confirmed by endothelial cell quantification and CT-
reconstructions of vascular casts. 
High levels of VeGF can predict vascular invasion of 
HCC and correlated with poor prognosis [1-2]. elevated 
VeGF is also a marker for poor response to locoregional 
treatment and is correlated with early recurrence [3-4]. 
PlGF levels are known to be elevated in a variety of 
cancers and is associated with poor prognosis in HCC 
[5-6]. The up-regulation of PlGF in this Den-model 
supports the theory that PlGF plays an essential role in 
the angiogenesis of HCC.
Soluble vascular endothelial growth factor receptor-1 (sVeGFR1), a 
naturally occurring soluble form of the VeGF receptor1, is an important 
negative counterpart of the VeGF signalling pathway. Therefore, we 
measured the serum levels of sVeGFR1. There was a slight increase 
of sVeGFR1 at 30W Den treatment, but no significant difference was 
seen between controls and 25W Den
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protein levels of VeGF in liver tissue. Asterisks (*) represent the 
significant P-values of the control group compared to Den-groups (* 
= p<0,05; ** = p<0,01 and *** = p < 0,001). These data support the 
theory that PLGF plays an important role in the pathogenesis of HCC.
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